Board summary
Key figures
67,701
Registered population
60.2% aged 18–64
20.2%
Aged 65+
ICB 19.0% · England 17.9%
3.4%
Ethnic minority (non-White)
1.2% Asian · England 9.6%
40.4%
In IMD quintile 1
ICB 31.9% · England 21.0%
~27,385
Core20 residents (est.)
Resident basis; registered basis ~28,154 · see page 3
12,050
Hypertension register
+8.08% in 3 yrs · England +5.60%
626
SMI register
47.9% of Halton (LAD)'s
1,901
COPD register
Reviews +8.38% in 3 yrs
Forecast to 2030
14,246
Hypertension patients, 2030
+2,196 on today
62.8%
QRISK ≥20% on statins, 2030
+1.01pp over 3 yrs
5.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD and hypertension care exceed national benchmarks.
Annual COPD reviews reach 80.6% (England 76.4%, growing +8.4% vs +2.8%), while hypertension treatment to target reaches 72.3% (England 70.3%, +7.3% vs +3.6%).
Lipid therapy and non-frail diabetes control lag.
QRISK ≥ 20% lipid therapy is 60.8% (England 63.6%, growing +1.7% vs +6.2%) and non-frail diabetes HbA1c control is 50.7% (England 57.4%).
Asthma review backlog and falling dementia register.
Asthma reviews at 62.8% (England 65.7%) leave about 1,800 of 4,843 patients unreviewed, while dementia prevalence fell 3.6% (England +6.0%).
Population, age and ethnicity
Patients aged 65+ make up 20.2% of the list, above England's 17.9% average
WIDNES PCN registers 67,701 patients across member practices. Patients aged 65+ make up 20.2% of the list (13,652 patients), higher than Halton (LAD) (17.5%), the ICB (19.0%), and England (17.9%). Those aged 18 to 64 represent 60.2% (40,760 patients), below Halton (LAD) (62.4%), the ICB (61.9%), and England (62.7%), while children aged 0 to 17 form 19.6% (13,289 patients; Halton (LAD) 20.0%, ICB 19.2%, England 19.6%). Census usual-resident estimates indicate 96.6% are White (Halton (LAD) 96.5%, ICB 93.0%, England 81.1%), with a 3.4% non-White ethnic minority share.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Halton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Halton LA) | 2,194 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 50.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Halton LA) | 1,120 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Halton LA) | 21.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 40.4% across the PCN with a 70.0 pp practice range
Across WIDNES PCN, 40.4% of registered patients live in Core20 areas, below Halton (LAD) (44.7%) but above NHS Cheshire and Merseyside Integrated Care Board (31.9%) and England (21.0%). Modelled weighted practice share is 41.6% (a 1.22 percentage point divergence). Practice shares span a 70.0 pp range, from 6.2% at Upton Rocks Primary Care to 76.3% at Oaks Place Surgery. Oaks Place Surgery has the highest share, while Peelhouse Medical Plaza has the largest estimated volume (5,549). Targeting must balance high-concentration outreach with high-volume clinical capacity.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
626
SMI register
0.92% recorded prevalence
452
Learning disability register
0.66% recorded prevalence
16
Care homes, 454 beds
In the PCN catchment
11.3%
Provide unpaid care
Halton (LAD), Census 2021
Recorded prevalence is 0.7% for learning disability (452 patients; England 0.6%) and 0.9% for severe mental illness (626 patients; England 1.0%), with 454 beds across 16 catchment care homes. Separate Halton borough data shows an 11.3% unpaid care rate and 6 rough sleepers in autumn 2025.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reach 84.7% (England 83.4%) and BMI recording reaches 82.5% (England 82.1%). Over 2023 to 2025, blood pressure check growth of +3.4 pp trailed England (+4.4 pp). Routine physical monitoring remains a local priority.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,050
Hypertension register
+8.08%
Register growth, 3 yrs
Halton (LAD) +6.68% · England +5.60%
+4.58pp
BP control, under 80
≤140/90 · +4.03pp aged 80+
+2,196
More patients by 2030
Forecast 14,246 (20.63%)
Hypertension case-finding and control
Hypertension QOF prevalence is 17.7% (12,050 patients), matching Halton (LAD) at 17.7% and above the ICB (16.8%) and England (15.2%). While treatment to target reaches 72.3% (England 70.3%, Halton 71.2%), the share with a recent blood pressure reading is 88.7% (England 90.0%, Halton 88.9%), and three-year recording growth (+2.3% over 2023 to 2025) lagged England (+3.6%). Crude prevalence does not establish undiagnosed disease, but varied across practices from 10.9% at Oaks Place Surgery to 19.6% at The Beeches Medical Ctr. Strong blood pressure control among monitored patients highlights an opportunity to expand routine annual checks across practices.
Lipids and statins
Lipid therapy for patients with QRISK ≥ 20% reaches 60.8%, trailing Halton (LAD) at 62.5%, the ICB at 63.2%, and England at 63.6%, with three-year growth (+1.7% over 2023 to 2025) behind England (+6.2%). Lower uptake compared to regional and national benchmarks could reflect unverified variation in primary-prevention prescribing.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 126,917 | £1.90 | £1.71 | £1.86 | £241,142 |
| Cardiovascular (all), 2025 | 194,565 | £4.68 | £4.37 | £3.33 | £910,564 |
In 2026, lipid-modifying drugs cost £1.90 per item across 126,917 items (£241,142 spend), compared with £1.87 in Halton (LAD), £1.86 in England, and £1.71 in the ICB; the PCN spends £5,077 more than at England's unit cost. This difference reflects unit cost rather than prescribing efficiency, case-mix, or formulary adherence.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.89%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.54%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.8% (1,901 patients), with reviews at 80.6% (England 76.4%), up +8.4% over 2023 to 2025 (England +2.8%). Conversely, asthma reviews reach 62.8% (England 65.7%), trailing England's 3-year growth (+2.9% vs +4.4%) and leaving about 1,800 patients unreviewed across the 4,843 register. For asthma patients aged 6-19, second-hand smoke recording is 75.0% (England 78.8%) alongside 2,284 items prescribed per 1,000 aged 5-19 (England 1,488). Focusing recall on paediatric asthma reviews could help address this unverified care gap.
Cancer register and children's immunisation
Cancer: QOF prevalence (all ages) is 4.5% at PCN level, above Halton (LAD) (4.4%), above NHS Cheshire and Merseyside Integrated Care Board (4.3%) and above England (3.8%). Crude prevalence does not establish unmet need or under-detection, but may reflect local demographic need or diagnostic recording.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, NHS Cheshire and Merseyside ICB diagnosed 55.5% of staged cancers at stage 1 or 2 (7,482 of 13,490 cases; England 55.3%), 19.5 pp below the 75.0% national ambition, requiring about 2,640 extra early-stage diagnoses. Known-stage coverage was 72.8% (13,490 of 18,522 cases; England 67.0%). Early diagnosis was 44.9% for bowel (England 47.0%) and 40.4% for lung (England 33.8%). PCN breast screening was 73.9% (England 69.9%) and cervical screening was 70.4% (England 66.8%). However, cervical screening lagged at Newtown Surgery (59.3%), Hough Green Health Park (64.9%), and The Beeches Medical Ctr (65.5%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Mersey and West Lancashire Teaching Hospitals NHS Trust, 62-day referral to treatment was 77.96% (7.0 pp below the 85.0% standard), while NHS Cheshire and Merseyside ICB reached 76.23%. For the 28-day faster diagnosis standard, the trust achieved 72.39% (2.6 pp below the 75.0% standard), whereas the ICB reached 77.25%. The 31-day combined treatment standard was 95.46% at the trust and 95.71% across the ICB against the 96.0% standard. These wider-system operational metrics reflect trust and ICB delivery rather than PCN performance, and local referral pathways have not been verified.
| Pathways within standard (%) | Mersey and West Lancashire | North Cheshire and Mersey | Liverpool | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 80.21 | 75.47 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 98.17 | 90.51 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 83.67 | 73.26 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | North Cheshire and Mersey | Liverpool | England |
|---|---|---|---|---|
| MRI | 14.04 | 0.53 | 6.42 | 21.40 |
| CT | 13.08 | 2.32 | 0.71 | 9.92 |
| Echocardiography | 34.88 | 28.04 | 12.55 | 28.48 |
| Colonoscopy | 18.04 | 15.98 | 33.14 | 30.83 |
| Gastroscopy | 18.17 | 20.24 | 44.99 | 29.02 |
| All 15 DM01 tests | 21.17 | 6.34 | 11.50 | 23.14 |
| Community services activity | Halton residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 19,830 | 541,280 |
| Referrals | 3,185 | 97,150 |
| Patients with a contact | 6,225 | 146,240 |
Community services (residents of Halton), Jun 2026 (provisional). Provisional June 2026 Community Services Dataset records show that Halton borough residents accounted for 19,830 community contacts, of which 11,325 contacts (57.1%) were with adults aged 65 and over. These figures describe wider borough activity among residents rather than PCN registered patients, and do not represent PCN performance.
Practice variation and patient experience
Phone access and immunisation achievement vary sharply across member practices
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Upton Rocks | 112 | 6.2 | 61.0% | 75.0% | 76.5% |
| Bevan | 120 | 28.2 | 28.1% | 77.3% | 74.7% |
| Beeches Medical | 110 | 57.1 | 51.0% | 63.8% | 73.9% |
| Hough Green | 117 | 67.7 | 64.5% | 72.2% | 72.9% |
| Oaks Place Surgery | 132 | 76.3 | 72.5% | 60.5% | 71.7% |
| Fir Park | 98 | 25.9 | 42.8% | 75.5% | 71.3% |
| Peelhouse Medical | 119 | 40.5 | 29.3% | 80.2% | 67.2% |
| Newtown Surgery | 118 | 60.3 | 44.4% | 76.4% | 64.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia prevalence fell 3.6% over 2023 to 2025 while England grew +6.0%
Between 2023 and 2025, WIDNES PCN trailed England across five relative three-year changes: dementia prevalence fell 3.6% (England +6.0%), QRISK ≥ 20% lipid therapy grew +1.7% (England +6.2%), and asthma reviews rose +2.9% (England +4.4%). Slower expansion also occurred for statins in diabetes without CVD at +0.8% (England +2.1%) and hypertension blood pressure recording at +2.3% (England +3.6%). Conversely, clinical strengths outpaced England in COPD reviews (+8.4% vs England +2.8%), blood pressure control under age 80 (+7.0% vs England +3.2%), and hypertension treated to target (+7.3% vs England +3.6%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
QRISK statin treatment
Asthma reviews
Diabetes statin (no CVD)
Hypertension BP reading
COPD reviews
BP control, under 80
Hypertension treated to target
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Halton (LAD) | Asset | PCN | Halton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (454 beds) | n/a | Schools (catchment) | 64 | n/a |
| Children's centres | 4 | 8 | Places of worship | 30 | 55 |
| Libraries | 1 | 2 | Primary schools (LA maintained) | 15 | 33 |
| Primary academies | 5 | 13 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma reviews reach 62.8% vs 65.7% in England and 63.4% in Halton (LAD), with 2023 to 2025 growth (+2.9%) trailing England (+4.4%); about 1,800 of 4,843 register patients lack a recorded review. For discussion: practices could run a single-template asthma recall offering flexible after-school slots and checking second-hand smoke recording. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Dementia register and coding audit
Dementia register prevalence is 0.8% (553 patients, matching England's 0.8%), but fell 3.6% over 2023 to 2025 while Halton (LAD) grew +2.2%, the ICB +6.2%, and England +6.0%. For discussion: practices could audit clinical records for uncoded memory clinic letters or cognitive assessments and review care-home register coding. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Option 3
Targeted COPD case-finding search
COPD prevalence is 2.8% (1,901 patients across 67,701 registered), above England (1.9%) and the ICB (2.5%) but below Halton (LAD) (3.2%), giving a benchmark gap range of -618 to +239 patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult service alignment (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Dual-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check recall (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension monitoring recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Primary care phone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Dementia register and coding audit (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
| Option 3 · Targeted COPD case-finding search (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
